Empagliflozin yields clinical benefit in patients hospitalized with acute HF: EMPULSE

empagliflozin yields clinical benefit in patients hospitalized with acute hf empulse

Sumary of Empagliflozin yields clinical benefit in patients hospitalized with acute HF: EMPULSE:

  • November 14, 2021 2 min read Source/Disclosures Published by: Source: Voors A, et al.
  • LBS.05. Building on the Foundations of Treatment: Advances in Heart Failure Therapy.
  • Presented at: American Heart Association Scientific Sessions;
  • Disclosures: The EMPULSE trial was funded by Boehringer Ingelheim and Eli Lilly.
  • Voors reports receiving research support and consultant fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novo Nordisk, Novartis and Roche Diagnostics.
  • Back to Healio In the EMPULSE trial, adults hospitalized with acute HF who received the SGLT2 inhibitor empagliflozin were 36% more likely than those on placebo to have clinical benefit at 90 days, including prevention of death and readmissions.
  • Voors “Patients experienced improvements regardless of the type of heart failure — HF with reduced ejection fraction or HF with preserved ejection fraction, de novo or chronic decompensated heart failure — or whether they had diabetes or not,” Adriaan A.
  • Voors, MD, cardiologist at University Medical Center Groningen in the Netherlands, said during a press conference at the American Heart Association Scientific Sessions.

Want to know more click here go to source.

From -

Close

Site Language


Popular Posts

714

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close